When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Celebrate the simple mathematical sequence that is hidden in everything from sunflower spirals to Da Vinci's paintings Discover why the sequence is considered nature's secret code, governing ...
Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. Who doesn’t love a good math holiday? Most people know about Pi ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Add Yahoo as a preferred source to see more of our stories on Google. A variation of a puzzle called the “pick-up sticks problem” asks the following question: If I have some number of sticks with ...
A variation of a puzzle called the “pick-up sticks problem” asks the following question: If I have some number of sticks with random lengths between 0 and 1, what are the chances that no three of ...
When Fibonacci introduced what would become an eponymous sequence, he did so using rabbits as an analogy. Breeding pairs of rabbits are able to multiply within their ranks infinitely. Unfortunately, ...
June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...